Use of HO-1 inducers and DOR o CB2 agonists in inflammatory pain

Developed by: Instituto de Investigación Biomédica Sant Pau (IIB Sant Pau)


The present invention relates to a combination comprising an heme oxygenase 1 inducer and a cannabinoid 2 receptor agonist or a selective δ-opioid receptor agonist for use in the prevention and/or treatment of inflammatory pain.

HO-1 inducers, DOR and CB2R agonists have shown antinociceptive effect when used individually in the treatment of inflammatory pain. Although literature suggests antagonic effects of theses agents in neuropathic pain induced by peripheranl nerve injury, the inventor has unexpectedly found that administration of an HO-1 inducer enhances the antinociceptive effects of DOR and CB2R agonists in the treatment of inflammatory pain, i.e. a synergistic effect is obtained by the combination of a HO-1 inducer and a DOR or CB2R agonist, providing thus a new potential strategy for management of inflammatory pain.

Responsable: Alfons Hervàs

Contacto (Tel./mail): ahervas(ELIMINAR)  / 93 553 78 69

En busca de codesarrolladores, En desarrollo
Health technology:
Medicamentos - Farma